ACTG 5178: SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。背景资料：这项研究的目的是找出是否长期治疗与聚乙二醇干扰素（PEG-IFN）减缓丙型肝炎引起的肝损害的速度也感染了艾滋病毒的人。 具体目的和程序（摘要）：第1部分：参与者将给予PEG-IFN和利巴韦林12周，如果他们从未接受过HCV治疗;他们过去曾接受过PEG-IFN，IFN或IFN和利巴韦林治疗长达一年，但已停止治疗12周;或者他们已经接受过某种形式的IFN治疗至少12周，但仍然患有HCV。治疗12周后，所有参与者将进行肝活检。 第二部分：对12周治疗没有表现出应答迹象的受试者将随机分配接受PEG-IFN单独治疗72周或继续研究治疗72周。 第三部分：对12周治疗有反应迹象的参与者将继续接受PEG-IFN和利巴韦林治疗72周，然后在研究中再接受24周的治疗。 意义（总结）：研究结果将提供给受试者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: The purpose of this study is to find out whether long-term treatment with pegylated-interferon (PEG-IFN) slows the rate of liver damage caused by hepatitis C in people also infected with HIV. Specific Aims and Procedures (summary): Part 1: Participants will be given PEG-IFN and ribavirin for 12 weeks if they have never been treated for HCV; they have been treated in the past with PEG-IFN, IFN or IFN and ribavirin for up to one year, but have been off treatment for 12 weeks; or they have been treated with some form of IFN for at least 12 weeks and still have HCV. After 12 weeks of treatment, all participants will have a liver biopsy. Part 2: Participants who do not show signs of responding to the 12 weeks of treatment will be assigned by chance to either receive PEG-IFN alone for 72 weeks or to continue on study off treatment for 72 weeks. Part 3: Participants who sign signs of responding to the 12 weeks of treatment will continue to receive PEG-IFN and ribavirin for 72 weeks and then be followed on study for an additional 24 weeks off treatment. Significance (summary): Study findings will be available to participants.